COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

31,620 Articles (22,913 medRxiv, 8,707 bioRxiv)

Most recent first Previous |  Page 173: Articles 1721-1730  | Next

Autoantibodies Targeting Angiotensin Converting Enzyme 2 Are Prevalent and Not Induced by SARS-CoV-2 Infection
Galipeau, Y., Castonguay, N., McCluskie, P. S., Sonoda, M. T., Keeshan, A., Collins, E., Arnold, C., Pelchat, M., Burns, K., Cooper, C., Langlois, M.-A.
10.1101/2024.11.18.24317488 — Posted: 2024-11-18
Immunosenescence profile is associated with increased susceptibility to severe COVID-19
Ventura, L. H. A., Torres, L., Camatta, G. C., Zamame, J., Coelho, M. M., Ramalho-Pinto, C. H., Gervazio, J., Caixeta, F., Nascimento, L., Oliveira, M. A., Martins, V. D., Oliveira, M. F., Costa, M. S., Sato, H. I., Guimaraes, H. C., Barbuto, R., Veiga, A. P., Ataide, N., Caetano, G. P., Rangon, S., Junior, M., Fortes, F. C., Zuccherato, L., Farias, E. S., Coelho, V., Avritchir, R., Souza, R., Ayupe, M. C., Loureiro, C., Neves, A. C. M., Passos, M. E., Leite, P., Teixeira, S., Tupinambas, U., Vilela, L. F., Silveira-Nunes, G., Maioli, T. U., Fonseca, D. M., Teixeira-Carvalho, A., Faria, A. M.
10.1101/2024.11.18.24317502 — Posted: 2024-11-18
Antibody evasiveness of SARS-CoV-2 subvariants KP.3.1.1 and XEC
Wang, Q., Guo, Y., Mellis, I. A., Wu, M., Mohri, H., Gherasim, C., Valdez, R., Purpura, L. J., Yin, M. T., Gordon, A., Ho, D. D.
10.1101/2024.11.17.624037 — Posted: 2024-11-18
Significantly enhancing antiviral efficacy by computational optimization and structural engineering of grafted nanobodies
HUO, L., Qin, Q., Tian, T., Zhang, X., He, X., Cao, Y., Zhang, T., Xu, Y., Huang, Q.
10.1101/2024.11.15.623776 — Posted: 2024-11-18
Chronic Viral Reactivation and Associated Host Immune Response and Clinical Outcomes in Acute COVID-19 and Post-Acute Sequelae of COVID-19
Maguire, C., Chen, J., Rouphael, N., Pickering, H., Phan, H. V., Glascock, A., Chu, V., Dandekar, R., Corry, D., Kheradmand, F., Baden, L. R., Selaky, R., McComsey, G. A., Haddad, E. K., Cairns, C. B., Pulendran, B., Fernandez-Sesma, A., Simon, V., Metcalf, J. P., Higuita, N. I. A., Messer, W. B., David, M. M., Nadeau, K. C., Kraft, M., Bime, C., Schaenman, J., Erle, D., Calfee, C. S., Atkinson, M. A., Brackenridge, S. C., Ehrlich, L. I. R., Montgomery, R. R., Shaw, A. C., Hough, C. L., Geng, L. N., Hafler, D. A., Augustine, A. D., Becker, P. M., Peters, B., Ozonoff, A., Kim-Schulze, S. H., Krammer, F., Bosinger, S., Eckalbar, W., Altman, M. C., Wilson, M., Guan, L., Kleinstein, S. H., IMPACC Network, , Smolen, K. K., Reed, E. F., Levy, O., Maecker, H., Hunt, P., Steen, H., Diray-Arce, J., Langelier, C. R., Melamed, E.
10.1101/2024.11.14.622799 — Posted: 2024-11-16
COVID-19 Associated Myocardial Injury and Arrhythmias
Mughal, M. S., Akbar, H., Mughal, W. A., Bansal, A., Mirza, H., Mazzaferro, N., Niaz, Z., Wasty, N.
10.1101/2024.11.13.24317287 — Posted: 2024-11-15
Transmission dynamics of COVID19 in the outbreak among healthcare workers at a university hospital in Rio de Janeiro, Brazil
Braga, J. U., Rocco Suassuna, J. H., Semeao de Souza, A. S.
10.1101/2024.11.13.24317283 — Posted: 2024-11-15
Clinical impact and cost-effectiveness of updated 2023/24 COVID-19 mRNA vaccination in high-risk populations in the United States
Joshi, K., Dronova, M., Paterak, E., Nguyen, V. H., Kopel, H., Mansi, J., Van de Velde, N., Beck, E.
10.1101/2024.11.15.24317369 — Posted: 2024-11-15
Human ace2 and tmprss2 polymorphisms for predicting susceptibility to tuberculosis and COVID-19 co-infection in Cameroonian cohort.
Kameni, M. N., Tchoupe, E. B., Kamdem, S. D., Bhalla, N., Paul, A. A. J., Arnaud, T. N., Neba, F. R., Nanda, R. K., Awuah, A. A.-A., Amuasi, J., Masumbe Netongo, P. M.
10.1101/2024.11.14.24317326 — Posted: 2024-11-15
Immunogenicity and safety of DS-5670d, an mRNA-based COVID-19 vaccine targeting omicron XBB.1.5: Results from a phase 3, randomized, active-controlled study in adults and children aged >=12 years
Takeshita, F., Kawamoto, A., Hashida, M., Ishida, K., Furihata, K., Ota, A., Takahashi, K., Sakakibara, S., Nakano, T.
10.1101/2024.11.14.24317321 — Posted: 2024-11-15

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).